Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

Hematol Oncol. 2022 Dec;40(5):857-863. doi: 10.1002/hon.3060. Epub 2022 Aug 14.


A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.

Keywords: COVID-19; convalescent plasma; disease severity; hematological malignancy; survival data.

Publication types

  • Multicenter Study

MeSH terms

  • COVID-19* / therapy
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / therapy
  • Humans
  • Retrospective Studies
  • SARS-CoV-2